Idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis Content
Rebecca Bascom, ATS 2021: MN-001 in Idiopathic Pulmonary Fibrosis
We were delighted to talk with Dr Rebecca Bascom (Penn State Hershey Medical Center, Hershey, PA, US) around her study investigating the use of MN-001 in patients with idiopathic pulmonary fibrosis. ‘A Single-Center, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of MN-001 (Tipelukast) in Subjects with Idiopathic Pulmonary Fibrosis.‘ was presented at […]
Toby Maher, ERS 2020 – Ziritaxestat in the Treatment of Idiopathic Pulmonary Fibrosis
We were delighted to catch up with our Editorial Board member, Prof. Toby Maher (University of Southern California, Los Angeles, CA, USA) during the ERS Virtual Congress, to discuss the ISABELA study in IPF (NCT03711162) and the challenges the trial has faced during the COVID-19 pandemic. Questions What are the major unmet needs in the […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!